Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets

NCT ID: NCT02522208

Last Updated: 2016-11-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2016-04-30

Brief Summary

This study will investigate cardiovascular parameters using echocardiographic and pharmacokinetics during a daily dose of BiDil and BiDil Extended Release (XR) compared to a study drug free day.

Detailed Description

A multiple-center, open-label, randomized, daily dose, two-sequence, two-way crossover pharmacodynamics (PD) and pharmacokinetic (PK) study of BiDil XR capsules and commercial BiDil tablets in Self-identified Black Patients, who are Slow Acetylators, with Heart Failure and have not received BiDil, isosorbide dinitrate (ISDN), or hydralazine hydrochloride (HCl) for at least 30 days prior to screening. The study consists of two doses of BiDil XR capsules (dosed at 0 hr and 9 hr) and three doses of BiDil tablets (dosed at 0 hr, 6 hr and 12 hr).

Conditions

Heart Failure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BiDil Extended Release (XR)

BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day

Group Type: EXPERIMENTAL

BiDil XR

Intervention Type: DRUG

fixed combination capsule

BiDil Immediate Release (IR)

Intervention Type: DRUG

fixed combination tablet

BiDil Immediate Release (IR)

BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day

Group Type: ACTIVE_COMPARATOR

BiDil XR

Intervention Type: DRUG

fixed combination capsule

BiDil Immediate Release (IR)

Intervention Type: DRUG

fixed combination tablet

Interventions

BiDil XR

fixed combination capsule

Intervention Type: DRUG

BiDil Immediate Release (IR)

fixed combination tablet

Intervention Type: DRUG

Other Intervention Names

BiDil capsules, hydralazine HCl + isosorbide dinitrate; BiDil tablets, hydralazine HCl + isosorbide dinitrate

Eligibility Criteria

Inclusion Criteria

• Self-identified Black, stable, chronic heart failure male or female subjects classified as having New York Heart Association (NYHA) Class II or III, diagnosed at least 3 months prior to Screening.
• Clinically stable outpatient, receiving standard, stable treatment regimen for heart failure (HF), at least 2 weeks prior to screening and throughout the duration of the trial. Subjects receiving beta-blockers must have been taking these for at least 3 months.
• All other medications must have been at a stable dose for at least 2 weeks prior to first dose
• Subjects must not have received BiDil, isosorbide dinitrate or hydralazine HCl for at least 30 days prior to Screening
• Have an adequate and demonstrable baseline Tricuspid regurgitation jet, visible inferior vena cava, and adequate right heart echocardiogram (with or without saline bubble contrast) allowing measurements to be made.
• Baseline PA systolic pressures > 35 mmHg
• Slow acetylator
• Adult subjects at least 18 years old or state-specific age of majority.
• Clinical lab tests negative for HIV, Hepatitis B surface antigen and Hepatitis C antibody.
• Urine testing negative for alcohol and drugs of abuse.
• Negative human chorionic gonadotropin (hCG) pregnancy test.
• Females must agree to avoid becoming pregnant or males must agree to use appropriate contraceptive methods with his partner(s), during the study and up to post 30 days from last dose of study drug.
• Females must be:
• unable to have children or
• where the partner is sterile OR
• willing to remain abstinent OR
• willing to use two effective methods of birth control.
• Willing and able to be confined for inpatient study periods and agree to study restrictions
• Ability to grant voluntary informed consent to participate in the study.

Exclusion Criteria

• Have significant valvular heart disease, hemodynamically significant obstructive hypertrophic cardiomyopathy, active myocarditis, or uncontrolled hypertension.
• Presence of severe, clinical right heart failure.
• Symptoms of unstable angina, a myocardial infarction, cardiac surgery, or percutaneous coronary intervention within 1 month prior to Screening
• Have coronary artery disease likely to require coronary artery bypass grafting or percutaneous coronary intervention during the ensuing 3 months.
• Had cardiac arrest or a sustained ventricular tachycardia considered life threatening and requiring intervention within 3 months, unless treated with implantable cardioverter-defibrillator.
• other causes of pulmonary hypertension that may confound pharmacodynamic assessments of heart failure
• Active malignancy or any non-cardiac life-limiting disease.
• Have significant hepatic, renal, or other disease that might confound the study results or present a risk to the subject.
• Had a stroke within the past 3 months.
• Received parenteral inotropic therapy within 1 month.
• Likelihood of undergoing cardiac transplantation or circulatory assist device implant over the ensuing 3 months.
• Symptomatic hypotension or blood pressure less than 110/70 mmHg at Screening.
• Any condition or risk factor which would jeopardize the evaluation of efficacy or safety or the ability to obtain effective echocardiography results.
• Currently require riociguat, hydralazine HCl, long-acting nitrates like ISDN, isosorbide mononitrate or sustained release nitroglycerin or phosphodiesterase 5 inhibitors.
• Alcohol or drug abuse within 1 year of study participation.
• Hypersensitivity, allergy, idiosyncratic reaction or adverse reaction to caffeine (if slow acetylator test is required), ISDN, hydralazine HCl, or any compounds with similar chemical characteristics.
• Received investigational drug within 30 days.
• Donated one pint or more of blood, plasma, or platelets within 30 days.
• Any subject who, in the opinion of the Investigator, cannot follow instructions.
• Pregnant, lactating or plan to get pregnant during the study
• History of lupus erythematous or lupus like syndrome.
• Use of herbal preparations, grapefruit, grapefruit juice, Seville oranges/juice or use of phosphodiesterase inhibitors within 2 weeks of first dose of study drug and throughout study.
• Employee of the Sponsor, investigative site or contract research organization.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Arbor Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steve D Caras, MD, PhD

Role: STUDY_CHAIR

Arbor Pharmaceuticals

Locations

Pinnacle Research Group, LLC

Anniston, Alabama, United States

Linfritz Research Institue Inc

Coral Gables, Florida, United States

Jacksonville Center for Clinical Research

Jacksonville, Florida, United States

Morehouse School of Medicine

Atlanta, Georgia, United States

Center for Medical Research, LLC

Providence, Rhode Island, United States

Countries

United States

Other Identifiers

AR06.009

Identifier Type: -

Identifier Source: org_study_id